Simple, sensitive and accurate stability indicating analytical method for dronedarone has been developed and validated using RP-HPLC technique. Developed method is used to evaluate the assay and related substances of dronedarone drug substance and tablets (Multaq?). The drug substance was subjected to the stress conditions such as hydrolysis (acid and base), oxidation, photolysis and thermal degradation as per International Conference on Harmonization (ICH) pre- scribed stress conditions to show the stability-indicating the nature of the method. Significant degradation was observed during acid and base hydrolysis, and peroxide degradation. The major degredants were identified by LC-MS, FTIR and 1H NMR spectral analysis. The chromatographic conditions were optimized using an impurity-spiked solution and the samples generated from forced degradation studies. In the developed HPLC method, the resolution between dronedar- one, process-related impurities, (namely Imp-1, Imp-2, Imp-3, Imp-4, Imp-5, Imp-6, Imp-7, Imp-8, Imp-9, Imp-10 and Imp-11) and degradation products were found to be greater than 1.5. The eleven potential process related impurities were separated on an Ascentis? Express C18 column (4.6 × 10 cm i.d., particle size 2.7 μm) at a flow rate of 1.2 mL.min-1. The LC method employed a linear gradient elution and the detection wavelength at 220 nm. The chroma- tographic behavior of all the impurities was examined under variable compositions of different solvents, temperatures and pH values.
 “Australian Public Assessment Report for Dronedarone Hydrochloride,” Submission No: PM-2008-3045-3, 2010. http://www.tga.gov.au/pdf/auspar/auspar-multaq.pdf
 Assessment Report for Multaq, “Evaluation of Medicines for Human Use,” European Medicines Agency, Procedure No. EMEA/H/C/001043, 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/001043/WC500044538.pdf
 Center for Drug Evaluation and Research, “Chemistry Review(s),” Application Number: 22-425, 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ChemR.pdf
 S. B. Bari, B. R. Kadam, Y. S. Jaiswal and A. A. Shirkhedkar, “Impurity Profile: Significance in Active Pharmaceutical Ingredient,” Eurasian Journal of Analytical Chemistry, Vol. 2, No. 1, 2007, pp. 177-189.
 C. Xie, S. L. Yang, D. F. Zhong, X. J. Dai and X. Y. Chen, “Simultaneous Determination of Dronedarone and Its Active Metabolite Debutyldronedarone in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study,” Journal of Chromatography B, Vol. 879, No. 28, 2011, pp. 3071-3075.
 D. Patel and A. Choudhury, “Development and Validation of Dronedarone HCl In Plasma by RP-HPLC Method Coupled with UV-Detector,” Inventi Impact: Biomedical Analysis, Vol. 2012, 2012, Article ID: Inventi:pba/47/12. http://www.inventi.in/Article/pba/47/12.aspx
 N. Tondepu1, S. S. Sait, K. V. Surendranath, R. K. Kaja1 and S. Kumar, “A Stability Indicating HPLC Method for Dronedarone in Bulk Drugs and Pharmaceutical Dosage Forms,” American Journal of Analytical Chemistry, Vol. 3, 2012, pp. 544-551. doi:10.4236/ajac.2012.38072
 A. Patel and J. Akhtar, “RP-HPLC Method Development and Validation of Dronedarone HCl in Its Pure Form and Tablet Dosage Form,” Journal of Chemical and Pharmaceutical Research, Vol. 4, No. 4, 2012, pp. 2173-2179.
 B. Dabhi, Y. Jadeja, M. Patel, H. Jebaliya, D. Karia and A. Shah, “Method Development and Validation of Stability- Indicating RP-HPLC Method for Quantitative Analysis of Dronedarone Hydrochloride in Pharmaceutical Tablets,” Scientific Pharmacology, in press, pp. 1209-1215.
 A. C. Mali, S. S. Ippar, M. S. Bodke, N. S. Patil and V. T. Mathad, “An Improved, and Efficient Process for the Production of Dronedarone Hydrochloride, an Antiarrhythmic Drug,” Organic Process Research & Development, Vol. 17, No. 5, 2013, pp. 863-868.